If you miss an appointment to receive your ofatumumab dose, contact your healthcare provider right away to reschedule. It is important to try to keep all of your appointments.
How Does It Work?
An antibody (also known as an immunoglobulin) is a protein made by the immune system. Antibodies attach to antigens, which are proteins found on foreign substances that enter the body. Once attached to the antigen, the antibody marks the substance for destruction by the immune system.
Ofatumumab is an antibody that is made in a laboratory (rather than a naturally occurring antibody). It works by binding to CD20, a specific antigen found on the surface of healthy cells and leukemia B cells (a type of white blood cell). By binding to the CD20 antigen on leukemia cells, ofatumumab signals the immune system to attack and destroy the leukemia cells.
Ofatumumab has been studied in people with CLL who failed certain other treatments. In this study, 42 percent of people given ofatumumab responded to the medication, as determined by the researchers conducting the study. The median length of response was 6.5 months.
This means that half of the people responded for more than 6.5 months, while half responded fewer than 6.5 months. There was no evidence to indicate the medication reduced symptoms or increased survival in those with CLL.
In studies in previously untreated people who were not good candidates for fludarabine-based treatment, adding ofatumumab to chlorambucil almost doubled the length of progression-free survival (the time it takes before the disease gets worse) compared to chlorambucil alone (22.4 months compared to 13.1 months).
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click